Back to News
Market Impact: 0.4
Palisade Bio Gets FDA Clearance For PALI-2108 IND In Crohn's Disease
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Palisade Bio received FDA clearance for its IND application for PALI-2108, enabling clinical development in moderate-to-severe Crohn's disease. The clearance is a positive regulatory milestone for the clinical-stage biotech's inflammatory and fibrotic disease pipeline and could materially affect PALI shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
PALI0.80
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Street Calls of The Week
- Florida’s new property tax cuts could defund the police, fire fighters and EMS in small towns, threatening ‘rural dark ages,’ former GOP lawmaker says
- Asia Markets Brace for More AI Volatility
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Paraguay’s ousted president charged over banking scandal